Breyanzi denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for breyanzi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Breyanzi: Experimental / Investigational

A denial classifying Breyanzi (lisocabtagene maraleucel) as "experimental" or "investigational" is one of the most legally vulnerable denial types available to insurers — because Breyanzi holds full FDA approval for defined indications. An experimental denial applied to an FDA-approved therapy in its approved indication is difficult for an insurer to sustain at external review.

This denial pattern typically occurs when Cigna's coverage policy has not been updated to reflect a recent FDA approval, when the request falls in the narrow gap between approval and policy update, or when the specific indication (e.g., an earlier line of therapy approved in a subsequent FDA action) is not yet reflected in the plan's formulary or coverage criteria.

## Why This Denial Is Appealable

FDA approval is the foundational standard most courts, arbitrators, and IROs use to distinguish established from experimental therapy. If your use of Breyanzi falls within an FDA-approved indication, the experimental classification is almost certainly wrong. Even where an insurer's policy lags an FDA approval, regulators and IROs routinely hold that FDA approval displaces an "experimental" label. For ERISA plans, applying an "experimental" denial to an FDA-approved therapy in a life-threatening condition may also implicate the plan's duty to apply benefit determinations in a consistent, non-arbitrary manner.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): File within 180 days of denial. Expedited review (72-hour decision) is available if delay would seriously jeopardize your health — request it in writing.
• External review (ACA §2719): After exhausting internal appeals, you have generally 4 months to request IRO review. For experimental/investigational denials involving a life-threatening condition, many states and federal rules provide expedited external review as well.
• Expedited external review: Specifically available under federal regulations for experimental denials in serious conditions — request this pathway explicitly.

## Documentation to Gather

• FDA approval letter / prescribing information for Breyanzi — confirm the exact approved indication and that your diagnosis and prior-treatment history match it
• Oncologist letter stating the specific FDA-approved indication under which Breyanzi is being prescribed, with confirmation that all eligibility requirements in the label are met
• Denial letter — identify the exact language Cigna used to classify Breyanzi as experimental; note whether their policy has a last-updated date that predates the relevant FDA approval
• Treatment history documenting prior lines of therapy and their outcomes, to confirm you meet the approved indication's prior-therapy requirements
• Applicable clinical guideline reference from the relevant hematology organization (e.g., NCCN) noting Breyanzi's inclusion — cite the organization without quoting specific version numbers or statistics

## Criteria-Mapping Structure

| Cigna's Experimental Basis | Your Rebuttal | |---|---| | Claimed lack of established efficacy | [FDA approval date and indication; oncologist confirmation of on-label use] | | Policy last-updated date | [If policy predates FDA action, state the approval date explicitly] | | Prior-therapy requirements in label | [List each prior line required; document your treatment history meeting them] | | Guideline recognition | [Name the guideline organization that includes Breyanzi; do not quote statistics] |

An appeal that leads with the FDA approval and maps your case precisely to the approved indication is the most powerful response to an experimental denial for Breyanzi.